MYB (6q23), ATM (11q22.3), +12, DLEU1 (13q14.3), TP53 (17p13)
Chronic Lymphocytic Leukemia(CLL)
The Vysis CLL Fish probe kit is indicated for detecting deletion of the LSI TP53 probe target (17p-) as an aid in identifying those patients with CLL for whom treatment with VENCLEXTA® (venetoclax) is indicated. Vysis CLL FISH Probe Kit is not intended for monitoring of residual disease
Fluorescence in situ Hybridization (FISH)
5mL peripheral blood in sodium heparin
3mL bone marrow in sodium heparin
Fixed cytogenetically prepared cells in sterile centrifuge tube with pellet visible in 3:1, Methanol:Acetic Acid
4°C to 25°C during transit, but specimens may be transported on refrigerated gel packs. Do not allow the gel pack to come in contact with the specimen. Do not freeze. Extreme temperatures should be avoided.
Clotted specimen; Specimens exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Leukemias are a diverse group of diseases often characterized by multiple genetic aberrations distributed across the genome. In some cases, the same genetic aberrations are shared by different types of leukemia. Fluorescence in situ hybridization (FISH) has improved the detection of genomic aberrations in chronic lymphocytic leukemia. Chromosomal aberrations are detected in approximately 82% of patients. The most frequent changes are deletion 13q (55%), deletion 11q (18%), trisomy 12 (16 %), deletion 17p (7%) and deletion 6q (6%). FISH can detect these abnormalities in either interphase or metaphase cells.